Who we are:
ICA Biotechnological & Pharmaceutical Joint Stock Company
We are one of the leading manufacturers of pharmaceutical and biotechnological products in Viet Nam. We began our business fifteen years ago and have a reputation for producing some of the highest quality medicines in the region. Our motto “Quality Without Compromise” expresses both the way we manufacture products and the methods we use to achieve our goals. We take great pride in the quality of our products, in our employees, and in our reputation.
What we do:
We manufacture pharmaceutical and biotechnology products for two markets:
The domestic market for wholesale pharmaceuticals to hospitals, pharmacies, and clinics.
The export market in SE Asia, Japan, and soon to the United States as well.
Where we are:
Main Office
Lot 10, Street 5, Viet Nam– Singapore Industrial Park, Thuan An, Binh Duong Province, Viet Nam
Tel: (+84) 6503757922 Fax: (+84) 6503757921
Email: info@icapharma.com
Website: www.icabiopharma.com
The Main Office is the location of the Board of Management as well as all other departments of the company. In addition, ICA’s GMP-compliant plant for manufacturing tablets, capsules, and sachets is located here.
Hanoi Branch Office
14 Lang Ha Street, Thanh Cong Ward, Ba Dinh District, Hanoi, Viet Nam
Tel: (+84) 47724011 Fax: (+84) 437724016
The Hanoi branch manages the distribution network for the north of Viet Nam. It conducts market research, monitors product consumption, and checks the quality of products stocked at the distributors and their agents. It also supervises Accounts Receivable for the area.
Executive Office in Ho Chi Minh City
56 Ngo Quang Huy Street, Thao Dien Ward, District 2, Ho Chi Minh City, Viet Nam
Tel: (+84) 35194268 Fax: (+84) 35194269
ICA maintains offices in Ho Chi Minh City for the convenience of both foreign and domestic guests. In addition, the company’s executive management frequently uses these offices. The dual conference rooms are invaluable assets for meeting with visitors or government officials.
Our History
Certifications
On December 20, 1999, Certificate of Formation 002/GP/TLDN issued by the Management Board of Vietnam Singapore Industrial Park formally established the company. Subsequently, ICA received Business Certificate 4602000034, issued on April 6, 2000, from the Binh Duong Service of Planning and Investment.
On May 5, 2003, we changed our name to ICA Pharmaceuticals Limited Company by renewing Business Certificate 4602000034, issued by Binh Duong Service of Planning and Investment.
On March 29, 2007, our name was modified again to ICA Biotechnological & Pharmaceutical Joint Stock Company. We were granted Business Certificate 4603000328 by Binh Duong Service of Planning and Investment with the charter capital of 68,880,000,000 VND.
On August 23, 2007, the Hanoi branch of ICA Biotechnological & Pharmaceutical Joint Stock Company was established when we received Business Certificate 0113019223, issued by The Hanoi Service of Planning and Investment.
On September 28, 2007, ICA Biotechnological & Pharmaceutical Joint Stock Company increased its charter capital to 116,500,000,000 VND under the same Business Certificate, 4603000328, issued by Binh Duong Service of Planning and Investment.
The Evolution of ICA
ICA began as a small pharmaceutical sales and distribution company on March 15, 1995. ICA developed and prospered over the years and as we grew, it became apparent that there was an opportunity to make a change from distributor to manufacturer.
In 1999, the construction of a pharmaceutical plant at the Vietnam Singapore Industrial Park began. ICA became the first privately owned Vietnamese pharmaceutical company to obtain a Good Manufacturing Practice (GMP) Certificate in Viet Nam.
In 2001, ICA began production at the new plant.
ICA established the finest quality assurance system attainable, following the strict demands of GMP and European standards for pharmaceutical manufacturing. Soon after beginning construction, ICA was awarded Good Laboratory Practice (GLP) and Good Storage Practice (GSP) Certificates.
ICA developed essential groups of drugs to serve hospitals and the health insurance system nationwide. These included anti-HIV medicine, analgesics, anti-inflammatory products as well as medicines to combat diabetes, high cholesterol, gastric and duodenal ulcers, and hepatitis.
ICA created new drugs for cardiovascular diseases, erectile dysfunction, treatment of eye disease, and new tonics and vitamins.
ICA began development of an imported product line.
In 2002, ICA purchased the license of the brand-name product Tobicom from Ahn-Gook Pharmaceutical Co., Ltd., for nearly $5,000,000 USD and began to manufacture Tobicom in 2003.
In 2003, ICA became the first Vietnamese pharmaceutical company producing low-priced anti-HIV drugs containing the active substance Indinavir.
In 2005, ICA was the first pharmaceutical company in Vietnam to create and offer the anti-erectile dysfunction medicine Adagrin, containing Sildenafil Citrate, to the market.
In 2006, ICA started to manufacture products that had previously been imported under license from some of our associates.
In 2007 ICA became an equity company.
In 2008, we changed our name to ICA Biotechnological and Pharmaceutical Joint Stock Company.
In 2009, we acquired Ranbaxy Viet Nam, Ltd., from Ranbaxy of Holland. We also acquired their entire Vietnamese product line and established a friendship that we believe holds great promise for the future.
In 2009 ICA acquired our partner, IC Viet Nam Co., Ltd., and merged it into the IC Group of Companies.
